SNDX vs PHAR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SNDX · Syndax Pharmaceuticals$8.72 ▼ 4.49%
PHAR · Pharming Group$11.54 ▼ 5.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SNDX -55.9%
- PHAR -32.6%
Head to head
| Metric | SNDX | PHAR |
|---|---|---|
| Price | $8.72 | $11.54 |
| Change today | ▼ 4.49% | ▼ 5.18% |
| Market cap | $785.05M | $816.78M |
| Return, 3 months | -55.4% | +0.7% |
| Return, year to date | -58.5% | -34.7% |
| Return, 1 year | -50.0% | -29.0% |
| P/E (TTM) | – | 35.0 |
| P/B | -45.7 | 2.8 |
| P/E percentile vs own 5y | 66th | 77th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +81.6% | +20.8% |
| Net profit growth (YoY) | +18.6% | +197.1% |
| Gross margin | 92.2% | 85.1% |
| Operating margin | -61.7% | 6.7% |
| Net margin | -72.3% | 6.3% |
| Return on equity | -426.4% | 8.7% |
| Analyst target vs. price | +332.0% | +238.0% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 28 | 45 |
| 30-day volatility | 117.2% | 59.3% |
| Max drawdown, 1 year | -66.0% | -57.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- PHAR is the largest of the group by market value.
- PHAR has returned the most over the past year.
- SNDX is growing revenue fastest.
- PHAR keeps the most profit per dollar of sales.
- PHAR has been the calmest stock over the last 30 days.